Soon-Shiong’s NantHealth tanks on STAT report of self-dealing; Bioversys, Aptuit forge antibiotic collab; Helix gets new CEO

STAT reported that biotech billionaire Patrick Soon-Shiong used a $12 million “gift” to the University of Utah as a carefully disguised boost to his cancer business, steering $10 million of that back into his hands under a contract that has raised questions about the way the money was handled. And the report has taken a big bite out of the share price of NantHealth $NH, which dropped 23%.

→ Basel-based Bioversys AG and Aptuit launched a joint collaboration aimed at the discovery of novel targets and molecules for Gram-negative bacteria.

→ Toronto-based Helix BioPharma has recruited a new CEO. CSO Heman Chao is adding the CEO title to his job description while Sven Rohmann will be chairman of the board as well as a strategic adviser.

→ San Francisco-based Velano Vascular has raised $17 million as it starts commercialization work on new, needle-free tech for drawing blood in hospitals.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->